

Appendix I- Changes Made

IN THE SPECIFICATION:

The title of the invention has been amended as follows:

[DETECTING AND TREATING EYE DISEASE] LATROPHILIN POLYNUCLEOTIDES

On page 1, lines 3-5, the specification has been amended as follows:

The present application was funded in part with government support under grant number [C033662] EY09580, from the National Eye Institute at the National Institutes of Health. The government has certain rights in this invention.

Appendix II - Pending Claims

1. A composition comprising an isolated nucleic acid, wherein said nucleic acid comprises a sequence that shares at least 96% identity with SEQ ID NO:1 or the complement of SEQ ID NO:1.
2. The composition of Claim 1, wherein said sequence shares at least 97% identity with SEQ ID NO:1 or the complement of SEQ ID NO:1.
3. The composition of Claim 1, wherein said sequence shares at least 98% identity with SEQ ID NO:1 or the complement of SEQ ID NO:1.
4. The composition of Claim 1, wherein said sequence is operably linked to a heterologous promoter.
5. The composition of Claim 1, wherein said sequence is contained within a vector.
7. A composition comprising an isolated nucleic acid, wherein said nucleic acid comprises a sequence encoding a peptide that shares at least 96% identity with SEQ ID NO:3.
8. The composition of Claim 7, wherein said peptide shares at least 97% identity with SEQ ID NO:3.
9. The composition of Claim 7, wherein said peptide shares at least 98% identity with SEQ ID NO:3.
10. The composition of Claim 7, wherein said sequence is operably linked to a heterologous promoter.

11. The composition of Claim 7, wherein said sequence is contained within a vector.

16. A composition comprising an isolated nucleic acid, wherein said nucleic acid comprises SEQ ID NO:1 or the complement of SEQ ID NO:1.